• +1-646-491-9876
    • +91-20-67278686

    Search

    Genital Herpes - Pipeline Review, H1 2017

    Genital Herpes - Pipeline Review, H1 2017

    • Report Code ID: RW0001709474
    • Category Pharmaceuticals
    • No. of Pages 102
    • Publication Month Mar-17
    • Publisher Name Global Markets Direct
    Genital Herpes - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Genital Herpes - Pipeline Review, H1 2017, provides an overview of the Genital Herpes (Infectious Disease) pipeline landscape.

    Genital herpes is a common sexually transmitted infection that affects both men and women. Genital herpes is caused by the herpes simplex virus (HSV) . Symptoms include decreased appetite, fever, general sick feeling (malaise) , muscle aches in the lower back, buttocks, thighs, or knees and swollen and tender lymph nodes in the groin during an outbreak. Treatment includes antiviral medications.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Genital Herpes - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Genital Herpes (Infectious Disease) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Genital Herpes (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Genital Herpes and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 6, 3, 18 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

    Genital Herpes (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Genital Herpes (Infectious Disease) .
    - The pipeline guide reviews pipeline therapeutics for Genital Herpes (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Genital Herpes (Infectious Disease) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Genital Herpes (Infectious Disease) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Genital Herpes (Infectious Disease)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Genital Herpes (Infectious Disease) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Genital Herpes (Infectious Disease) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Genital Herpes - Overview
    Genital Herpes - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Genital Herpes - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Genital Herpes - Companies Involved in Therapeutics Development
    Abivax SA
    Admedus Ltd
    AiCuris GmbH & Co KG
    Biomere LLC
    Foamix Pharmaceuticals Ltd
    Genocea Biosciences Inc
    GenVec Inc
    Immune Design Corp
    JN-International Medical Corp
    N & N Pharmaceuticals Inc
    NanoBio Corp
    NanoViricides Inc
    Profectus BioSciences Inc
    Redbiotec AG
    Sanofi Pasteur SA
    Starpharma Holdings Ltd
    Tomegavax Inc
    Vaccibody AS
    Vaxart Inc
    Vical Inc
    Genital Herpes - Drug Profiles
    ABX-196 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    acyclovir - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Aspidasept - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    astodrimer - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    G-103 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GEN-003 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    genital herpes (virus like particle) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    genital herpes vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    genital herpes vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    genital herpes vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    genital herpes vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    genital herpes vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GV-2207 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    herpes simplex virus [type 1, 2] vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    herpes simplex virus 2 vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    herpes simplex virus 2 vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    herpes simplex virus 2 vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    herpes simplex virus 2 vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    herpes simplex virus 2 vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    HSV-529 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NN-001 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pritelivir - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Profavax HSV-1 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Profavax HSV-2 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule for Genital Herpes - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Theravax HSV-1 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Theravax HSV-2 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VCLHB-01 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VCLHM-01 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VTMX-004 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Genital Herpes - Dormant Projects
    Genital Herpes - Discontinued Products
    Genital Herpes - Product Development Milestones
    Featured News & Press Releases
    Mar 06, 2017: NanoBio Receives SBIR Grant For Genital Herpes Vaccine
    Jan 05, 2017: Genocea Announces Positive 6-Month Results from GEN-003 Phase 2b Clinical Trial
    Dec 14, 2016: Genocea R&D Day Highlighted Lead Program, GEN-003, for the Treatment of Genital Herpes and Introduced Immuno-Oncology Programs & Strategy
    Dec 01, 2016: AiCuris Announces Start of LipP 1: First Subject Enrolled in the Clinical Phase 2 Trial with Topical Pritelivir for the Treatment of recurrent Labial Herpes
    Oct 28, 2016: Genocea Presents New 12 month Data on Genital Herpes Immunotherapy GEN-003 at IDWeek 2016
    Oct 19, 2016: Admedus Announces Positive Unblinded HSV-2 Phase II Interim Data
    Sep 29, 2016: Genocea's Genital Herpes Immunotherapy GEN-003 Demonstrates Significant Reduction of Viral Shedding in Phase 2b Clinical Trial
    Jun 20, 2016: A novel therapy for genital herpes engages immune cells to provide significant patient benefits
    Jun 20, 2016: Vicals Phase 1/2 Trial Data Presented at ASM 2016 Shows Bivalent Vaccine Imparts Reduction in Genital Herpes Lesions Durable to 9 Months
    Jun 09, 2016: Genocea Showcases Potential of Genital Herpes Immunotherapy GEN-003 at ASM Microbe 2016
    Mar 31, 2016: Genital Herpes Immunotherapy GEN-003 Shows Sustained Reduction of Viral Shedding Rate, Durable Impact on Clinical Disease 12 Months Post-Dosing
    Mar 04, 2016: Interim HSV-2 Phase II clinical trial data encouraging
    Feb 03, 2016: Model helps decide drug dose for clinical testing
    Jan 29, 2016: Genocea Commences Dosing in Phase 2b Study for Genital Herpes Treatment, GEN-003
    Oct 07, 2015: Genocea Announces Positive Durability Data from 6-Month Analysis of Phase 2 Clinical Trial of Genital Herpes Immunotherapy GEN-003
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Genital Herpes, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Genital Herpes - Pipeline by Abivax SA, H1 2017
    Genital Herpes - Pipeline by Admedus Ltd, H1 2017
    Genital Herpes - Pipeline by AiCuris GmbH & Co KG, H1 2017
    Genital Herpes - Pipeline by Biomere LLC, H1 2017
    Genital Herpes - Pipeline by Foamix Pharmaceuticals Ltd, H1 2017
    Genital Herpes - Pipeline by Genocea Biosciences Inc, H1 2017
    Genital Herpes - Pipeline by GenVec Inc, H1 2017
    Genital Herpes - Pipeline by Immune Design Corp, H1 2017
    Genital Herpes - Pipeline by JN-International Medical Corp, H1 2017
    Genital Herpes - Pipeline by N & N Pharmaceuticals Inc, H1 2017
    Genital Herpes - Pipeline by NanoBio Corp, H1 2017
    Genital Herpes - Pipeline by NanoViricides Inc, H1 2017
    Genital Herpes - Pipeline by Profectus BioSciences Inc, H1 2017
    Genital Herpes - Pipeline by Redbiotec AG, H1 2017
    Genital Herpes - Pipeline by Sanofi Pasteur SA, H1 2017
    Genital Herpes - Pipeline by Starpharma Holdings Ltd, H1 2017
    Genital Herpes - Pipeline by Tomegavax Inc, H1 2017
    Genital Herpes - Pipeline by Vaccibody AS, H1 2017
    Genital Herpes - Pipeline by Vaxart Inc, H1 2017
    Genital Herpes - Pipeline by Vical Inc, H1 2017
    Genital Herpes - Dormant Projects, H1 2017
    Genital Herpes - Dormant Projects, H1 2017 (Contd..1) , H1 2017
    Genital Herpes - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Genital Herpes, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Abivax SA
    Admedus Ltd
    AiCuris GmbH & Co KG
    Biomere LLC
    Foamix Pharmaceuticals Ltd
    Genocea Biosciences Inc
    GenVec Inc
    Immune Design Corp
    JN-International Medical Corp
    N & N Pharmaceuticals Inc
    NanoBio Corp
    NanoViricides Inc
    Profectus BioSciences Inc
    Redbiotec AG
    Sanofi Pasteur SA
    Starpharma Holdings Ltd
    Tomegavax Inc
    Vaccibody AS
    Vaxart Inc
    Vical Inc

    Request for Sample

    Report Url http://www.reportsweb.com//genital-herpes-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//genital-herpes-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//genital-herpes-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments